Uplizna launch is a ‘testament’ to NC’s prowess in drug R&D
In June, the U.S. Food and Drug Administration approved the therapy – brand named Uplizna – to intravenously treat neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-AQP4 antibody positive. It’s only the second approved drug for the illness.
Read More
